Olutasidenib in post-venetoclax patients with mutant isocitrate dehydrogenase 1 (mIDH1) acute myeloid leukemia (AML)

被引：8

作者：

Cortes, Jorge ^{[1
,15
]}

Jonas, Brian A. ^{[2
]}

Schiller, Gary ^{[3
]}

Mims, Alice ^{[4
]}

Roboz, Gail J. ^{[5
,6
]}

Wei, Andrew H. ^{[7
]}

Montesinos, Pau ^{[8
]}

Ferrell, P. Brent ^{[9
]}

Yee, Karen W. L. ^{[10
]}

Fenaux, Pierre ^{[11
]}

Schwarer, Anthony ^{[12
,13
]}

Watts, Justin M. ^{[14
]}

机构：

[1] Augusta Univ, Georgia Canc Ctr, Dept Med, Augusta, GA USA

[2] Univ Calif Davis, Dept Internal Med, Sch Med, Sacramento, CA USA

[3] Univ Calif Los Angeles, David Geffen Sch Med, Dept Internal Med Hematol Oncol, Los Angeles, CA USA

[4] Ohio State Univ, Div Hematol, Columbus, OH USA

[5] Weill Cornell Med, Dept Hematol & Med Oncol, New York, NY USA

[6] New York Presbyterian Hosp, New York, NY USA

[7] Alfred Hosp, Dept Haematol, Melbourne, Australia

[8] Hosp Univ & Politecn La Fe, Dept Hematol, Valencia, Spain

[9] Vanderbilt Univ, Med Ctr, Dept Med, Nashville, TN USA

[10] Univ Hlth Network, Princess Margaret Canc Ctr, Canc Clin Res Unit, Toronto, ON, Canada

[11] Univ Paris 07, Hop St Louis, Serv Hematol Sr, Paris, France

[12] Monash Univ, Box Hill Hosp, Dept Hematol, Melbourne, Australia

[13] Eastern Hlth Clin Sch, Melbourne, Australia

[14] Univ Miami, Sylvester Comprehens Canc Ctr, Dept Med, Div Hematol, Miami, FL USA

[15] Augusta Univ, Georgia Canc Ctr, 1410 Laney Walker Blvd, CN2222, Augusta, GA 30912 USA

来源：

LEUKEMIA & LYMPHOMA | 2024年 / 65卷 / 08期

关键词：

Olutasidenib; acute myeloid leukemia; IDH1; mutation; ADULTS;

D O I：

10.1080/10428194.2024.2333451

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Olutasidenib, a potent, selective, oral, mutant isocitrate dehydrogenase 1 (mIDH1) inhibitor, is FDA-approved for relapsed/refractory (R/R) acute myeloid leukemia (AML). Here we report efficacy and safety of olutasidenib in 18 patients with mIDH1 AML who were relapsed (10), refractory (6) or had complete remission with incomplete hematologic recovery (CRi; 2) to a venetoclax combination. Of the 16 patients who were R/R, 4 (25%) achieved complete remission (CR), one (6.3%) achieved CR with partial hematologic recovery (CRh), and 7 (43.8%) achieved a composite complete remission (CRc). Median time to CRc was 1.9 months (range 1-2.8). As of data cutoff (18 June 2021), median duration of CRc was not reached (range, 1.2-NR, ongoing at 30.4+ months). Both patients with CRi at study entry achieved a CR. Safety was consistent with the overall profile of olutasidenib. Olutasidenib offers a valuable treatment option for patients with mIDH1 AML previously treated with venetoclax.

引用

页码：1145 / 1152

页数：8

共 17 条

[1] Efficacy of FLT3 and IDH1/2 inhibitors in patients with acute myeloid leukemia previously treated with venetoclax [J].

Bewersdorf, Jan Philipp ;

Shallis, Rory M. ;

Derkach, Andriy ;

Goldberg, Aaron D. ;

Stein, Anthony ;

Stein, Eytan M. ;

Marcucci, Guido ;

Zeidan, Amer M. ;

Shimony, Shai ;

DeAngelo, Daniel J. ;

Stone, Richard M. ;

Aldoss, Ibrahim ;

Ball, Brian J. ;

Stahl, Maximilian .

LEUKEMIA RESEARCH, 2022, 122

[2] Structure-Based Design and Identification of FT-2102 (Olutasidenib), a Potent Mutant-Selective IDH1 Inhibitor [J].

Caravella, Justin A. ;

Lin, Jian ;

Diebold, R. Bruce ;

Campbell, Ann-Marie ;

Ericsson, Anna ;

Gustafson, Gary ;

Wang, Zhongguo ;

Castro, Jennifer ;

Clarke, Andrea ;

Gotur, Deepali ;

Josephine, Helen R. ;

Katz, Marie ;

Kershaw, Mark ;

Yao, Lili ;

Toms, Angela, V ;

Barr, Kenneth J. ;

Dinsmore, Christopher J. ;

Walker, Duncan ;

Ashwell, Susan ;

Lu, Wei .

JOURNAL OF MEDICINAL CHEMISTRY, 2020, 63 (04) :1612-1623

[3] Olutasidenib (FT-2102) induces durable complete remissions in patients with relapsed or refractory IDH1-mutated AML [J].

de Botton, Stephane ;

Fenaux, Pierre ;

Yee, Karen ;

Recher, Christian ;

Wei, Andrew H. ;

Montesinos, Pau ;

Taussig, David C. ;

Pigneux, Arnaud ;

Braun, Thorsten ;

Curti, Antonio ;

Grove, Carolyn ;

Jonas, Brian A. ;

Khwaja, Asim ;

Legrand, Ollivier ;

Peterlin, Pierre ;

Arnan, Montserrat ;

Blum, William ;

Cilloni, Daniela ;

Hiwase, Devendra K. ;

Jurcic, Joseph G. ;

Krauter, Juergen ;

Thomas, Xavier ;

Watts, Justin M. ;

Yang, Jay ;

Polyanskaya, Olga ;

Brevard, Julie ;

Sweeney, Jennifer ;

Barrett, Emma ;

Cortes, Jorge .

BLOOD ADVANCES, 2023, 7 (13) :3117-3127

[4] Azacitidine and Venetoclax in Previously Untreated Acute Myeloid Leukemia [J].

DiNardo, C. D. ;

Jonas, B. A. ;

Pullarkat, V. ;

Thirman, M. J. ;

Garcia, J. S. ;

Wei, A. H. ;

Konopleva, M. ;

Doehner, H. ;

Letai, A. ;

Fenaux, P. ;

Koller, E. ;

Havelange, V. ;

Leber, B. ;

Esteve, J. ;

Wang, J. ;

Pejsa, V. ;

Hajek, R. ;

Porkka, K. ;

Illes, A. ;

Lavie, D. ;

Lemoli, R. M. ;

Yamamoto, K. ;

Yoon, S. -S. ;

Jang, J. -H. ;

Yeh, S. -P. ;

Turgut, M. ;

Hong, W. -J. ;

Zhou, Y. ;

Potluri, J. ;

Pratz, K. W. .

NEW ENGLAND JOURNAL OF MEDICINE, 2020, 383 (07) :617-629

[5] Targeting Acute Myeloid Leukemia with Venetoclax; Biomarkers for Sensitivity and Rationale for Venetoclax-Based Combination Therapies [J].

Griffioen, Mila S. ;

de Leeuw, David C. ;

Janssen, Jeroen J. W. M. ;

Smit, Linda .

CANCERS, 2022, 14 (14)

[6] The predictive value of hierarchical cytogenetic classification in older adults with acute myeloid leukemia (AML): analysis of 1065 patients entered into the United Kingdom Medical Research Council AML11 trial [J].

Grimwade, D ;

Walker, H ;

Harrison, G ;

Oliver, F ;

Chatters, S ;

Harrison, CJ ;

Wheatley, K ;

Burnett, AK ;

Goldstone, AH .

BLOOD, 2001, 98 (05) :1312-1320

[7] Molecular landscape of acute myeloid leukemia in younger adults and its clinical relevance [J].

Grimwade, David ;

Ivey, Adam ;

Huntly, Brian J. P. .

BLOOD, 2016, 127 (01) :29-41

[8] Therapies for acute myeloid leukemia in patients ineligible for standard induction chemotherapy: a systematic review [J].

Heuser, Michael ;

Fernandez, Cedric ;

Hauch, Ole ;

Klibanov, Olga M. ;

Chaudhary, Tanushree ;

Rives, Vincent .

FUTURE ONCOLOGY, 2023, 19 (11) :789-810

[9] Outcomes with molecularly targeted agents as salvage therapy following frontline venetoclax plus hypomethylating agent in adults with acute myeloid leukemia: A multicenter retrospective analysis [J].

Khanna, Vishesh ;

Azenkot, Tali ;

Liu, Selina Qiuying ;

Gilbert, Jason ;

Cheung, Edna ;

Lau, Kimberly ;

Pollyea, Daniel A. ;

Traer, Elie ;

Jonas, Brian A. ;

Zhang, Tian Y. ;

Mannis, Gabriel N. .

LEUKEMIA RESEARCH, 2023, 131

[10] Outcomes of relapsed or refractory acute myeloid leukemia after front-line hypomethylating agent and venetoclax regimens [J].

Maiti, Abhishek ;

Rausch, Caitlin R. ;

Cortes, Jorge E. ;

Pemmaraju, Naveen ;

Daver, Naval G. ;

Ravandi, Farhad ;

Garcia-Manero, Guillermo ;

Borthakur, Gautam ;

Naqvi, Kiran ;

Ohanian, Maro ;

Short, Nicholas J. ;

Alvarado, Yesid ;

Kadia, Tapan M. ;

Takahashi, Koichi ;

Yilmaz, Musa ;

Jain, Nitin ;

Kornblau, Steven ;

Montalban-Bravo, Guillermo ;

Sasaki, Koji ;

Andreeff, Michael ;

Bose, Prithviraj ;

Ferrajoli, Alessandra ;

Issa, Ghayas C. ;

Jabbour, Elias J. ;

Masarova, Lucia ;

Thompson, Philip A. ;

Wang, Sa ;

Konoplev, Sergej ;

Pierce, Sherry A. ;

Ning, Jing ;

Qiao, Wei ;

Welch, John S. ;

Kantarjian, Hagop M. ;

DiNardo, Courtney D. ;

Konopleva, Marina Y. .

HAEMATOLOGICA, 2021, 106 (03) :894-898

← 1 2 →